$7.58
1.75% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US30205M1018
Symbol
XCUR

Exicure Inc Stock price

$7.58
+0.31 4.26% 1M
-2.76 26.69% 6M
-6.09 44.55% YTD
+5.08 203.44% 1Y
-3.47 31.40% 3Y
-340.42 97.82% 5Y
-457.42 98.37% 10Y
-457.42 98.37% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.13 1.75%
ISIN
US30205M1018
Symbol
XCUR
Industry

Key metrics

Basic
Market capitalization
$43.5m
Enterprise Value
$33.1m
Net debt
positive
Cash
$10.4m
Shares outstanding
6.3m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.8
Financial Health
Equity Ratio
45.0%
Return on Equity
-143.3%
ROCE
-42.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-7.1m | -
EBIT
$-7.1m | -
Net Income
$-5.9m | -
Free Cash Flow
$-4.1m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
35.2% | -
EBIT
36.8% | -
Net Income
56.0% | -
Free Cash Flow
45.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-0.6
Short interest
2.0%
Employees
7
Rev per Employee
$70.0k
Show more

Is Exicure Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Exicure Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

Hold
50%
Sell
50%

Financial data from Exicure Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.33 6.33
36% 36%
-
- Research and Development Expense 0.81 0.81
12% 12%
-
-7.06 -7.06
35% 35%
-
- Depreciation and Amortization 0.08 0.08
79% 79%
-
EBIT (Operating Income) EBIT -7.14 -7.14
37% 37%
-
Net Profit -5.86 -5.86
56% 56%
-

In millions USD.

Don't miss a Thing! We will send you all news about Exicure Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exicure Inc Stock News

Negative
The Motley Fool
4 days ago
Exicure Posts Wider Loss in Fiscal Q2
Neutral
Business Wire
4 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.
Neutral
Business Wire
8 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.
More Exicure Inc News

Company Profile

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Head office United States
CEO Andy Yoo
Employees 7
Founded 2011
Website www.exicuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today